INTRODUCTION
Morbilliviruses have emerged as potent pathogens of pinnipeds and cetaceans (Duignan et al., 1995b) . Four morbilliviruses are known to infect various species of marine mammals: Phocine distemper virus (PDV), porpoise morbillivirus (PMV), dolphin morbillivirus (DMV), and pilot whale morbillivirus (PWMV; Taubenberger et al., 2000; Di Guardo et al., 2005) and since 1987, at least eight mass-mortality events affecting free-living pinniped and cetacean populations worldwide have been attributed to Morbillivirus (subfamily Paramyxovirinae, family Paramyxoviridae) infection. The etiologic agents, epidemiology, pathogenesis, clinical signs, and pathology associated with marine mammal morbillivirus infection have been reviewed in detail (Kennedy, 1998; Van Bressem et al., 2001; Di Guardo et al., 2005) . Dolphin, porpoise, and pilot whale morbilliviruses are considered strains of the same virus species, and they are currently classified in the species cetacean morbillivirus (CMV ; Di Guardo et al., 2005) . CMV infection has a worldwide distribution (Van Bressem et al., 1998 ; however, there is limited information concerning CMV infection in cetaceans in Australian waters Van Bressem et al., 2001 ). Morbillivirus infection is endemic in several cetacean species including pilot whales (Globicephala spp.; Duignan et al., 1995a) . The epidemiologic role of subclinically infected animals may be more important than that played by clinically affected animals, as subclinically infected animals may serve as reservoirs of infection for other naïve cetaceans with which they associate (of the same or other species) resulting in clinical morbillivirus-induced disease, including epidemics Di Guardo et al., 2005) .
Most marine mammals diagnosed with morbilliviral disease are washed ashore dead or are found stranded in a moribund state and die shortly thereafter (Reidarson et al., 1998) , with some displaying neurologic or behavioral changes (Di Guardo et al., 2005) . The first confirmed case of fatal morbillivirus infection in a cetacean in the southern hemisphere was recently described in an Australian offshore bottlenose dolphin (Tursiops truncatus; Stone et al., 2011) ; therefore CMV infection should be included in the differential diagnosis of disease in cetaceans in Australia, particularly if they display neurologic signs (Stone et al., 2011) . Our aim was to describe the prevalence of antibodies to CMV infection in live stranded, injured, and trapped cetaceans in southeastern Queensland and northern New South Wales, Australia, and to compare prevalence by species, year sampled, age, sex, circumstances found, health status, and available pathology data. Given the potential for CMV transmission to captive cetaceans when stranded or injured wild animals are hospitalized and rehabilitated at marine parks and zoos, we also assessed CMV antibody prevalence in captive dolphins at Sea World, Gold Coast, southeastern Queensland.
MATERIALS AND METHODS

Wild cetaceans
Blood samples were collected from 27 cetaceans of eight species: Peponocephala (Reif et al., 2008) , excluding animals with purely traumatic injuries. Animals were identified to species and categorized as juvenile, subadult, or adult, according to biologic and morphometric parameters (Jefferson et al., 1993; Carwardine, 1995; Hale et al., 2000) . The sex and location of each animal was recorded and, depending on the circumstance in which they were found, animals were listed as stranded, injured, or trapped. Seventeen animals subsequently died or were euthanatized. Necropsies were performed on 16 of these, with multiple specimens from each animal submitted for routine histopathology, bacteriology, and/or fungal culture. Histopathology and culture samples were submitted to multiple laboratories over the sampling interval with available pathology data also included within this study. Nine animals were released either immediately or following hospitalization and rehabilitation; one remains in captivity. Immunohistochemistry (IHC) for morbillivirus antigen (wild cetacean identity numbers 20, 24, and 27; Table 1 ) and reverse transcription polymerase chain reaction (RT-PCR) for detection of morbilliviral RNA (numbers 5, 20, and 24; Table 1 ) were performed on formalin-fixed paraffin embedded brain or lung tissue specimens at the Commonwealth Scientific and Industrial Research Organisation (CSIRO), Australian Animal Health Laboratory (AAHL), Geelong, Victoria, Australia as previously reported (Stone et al., 2011) .
Captive cetaceans
Blood samples were collected from 13 captive cetaceans, of two species: T. aduncus and T. truncatus, at Sea World, Gold Coast, southeastern Queensland. Animals were sampled between November 2005 and January 2011 as part of routine health status monitoring or for disease investigation of animals that were clinically unwell. Animals were categorized as juvenile, subadult, or adult according to capture/captive breeding records or biologic and morphometric parameters (Carwardine, 1995; Hale et al., 2000) . None of these captive animals had been previously sampled as part of the wild population study.
CMV serum neutralization test
Following blood clotting and centrifugation, sera were stored at 220 C until shipment to the Athens Veterinary Diagnostic Laboratory, University of Georgia (Athens, Georgia, USA). Sera were shipped frozen with ice bricks, thawing en route. All serologic analyses were performed during 2010 and 2011.
The CMV SNT was performed with the use of the Belfast strain of DMV grown in Vero cells as previously described (Saliki and Lehenbauer, 2001) . Briefly, serial twofold dilutions of heat-inactivated sera were made in columns of 96-well plates with the use of Dulbecco's minimum essential medium, starting at a 1:2 dilution. An equal volume (25 ml) of the virus containing about 100 50% tissue culture infective doses was added to duplicate columns. The virus-serum mixtures were incubated at 37 C for 1 hr in 5% CO 2 and a Vero cell suspension (150 ml containing 10 4 cells/well) was added. The plates were incubated at 37 C in 5% CO 2 for 4 days. The test was read by examining cell monolayers under an inverted microscope for virus-specific cytopathic effect (CPE). Antibody titers were expressed as the reciprocal of the highest dilutions of sera that completely neutralized CPE in duplicate wells. Titers $8 were considered positive for morbillivirus antibody.
Statistical analyses
Prevalences of CMV antibody were compared within wild cetaceans (n527) by species, year of sampling, age, sex, circumstance in which the animal was found, health status, and available pathology findings. Sample size for comparisons between species was sufficiently large for only P. electra and T. aduncus. For analyses, years of sampling were categorized into 2005-2006, 2007-2008, and 2009-2011 . Circumstance was categorized as stranded or nonstranded (i.e., injured or trapped animals) and clinical health status was categorized as clinically diseased or nondiseased (i.e., clinically healthy or traumatized). Animals with histopathology data were classified as having pulmonary or central nervous system inflammation or not. Exact Fisher's confidence intervals for prevalences were calculated with the use of the Describe module (version 2.27) of WinPepi (version 11.4: Abramson, 2011) . Differences in antibody prevalence between groups were assessed with the use of two-tailed Fisher's exact tests, calculated with the use of the Compare2 module (version 2.51) of WinPepi.
RESULTS
Wild cetaceans
Thirteen of 27 (48.1%) tested cetaceans in five of the eight species had detectable antibody to CMV (Table 1) . Prevalences by species were P. electra, 83% (5/6); T. aduncus, 29% (4/14); L. hosei, 100% (1/1); M. novaengliae, 0% (0/1); F. attenuata, 0% (0/1); S. chinensis, 0% (0/1); T. truncatus, 100% (2/2); and B. edeni, 100% (1/1). Prevalences differed significantly (P50.05) between P. electra (83%; 95% confidence interval [CI] 35.9-99.5%) and T. aduncus (29%; 95% CI 8.4-58.1%).
The prevalence of antibody to CMV did not differ significantly between males (44%, 7/16) and females (55%, 6/11; P50.70) or by age groups (37%, 3/8; 62%, 5/8; and 45%, 5/ 11) for juveniles, subadults, and adults, respectively (P50.71). Antibody prevalences for the three pooled sample year groups were 56% (5/9) in 2005-2006, 29% (2/7) in [2007] [2008] , and 55% (6/11) in 2009-2011 and were not significantly different (P50.555). Prevalences did not differ significantly (P50.420) between stranded (56%, 10/18) and nonstranded (33%, 3/9) animals. However, the antibody prevalence in clinically diseased animals (69%, 11/16) was significantly higher than that in nondiseased (18%, 2/11) animals (P50.018).
Antibody prevalence in animals with histopathologic evidence of pulmonary or central nervous system inflammation (62%, 8/13) was not significantly different from that in animals without such pathology (67%, 2/3; P51.00). Animals without histopathology data were excluded from this analysis. Morbillivirus-specific IHC, performed on samples from three wild cetaceans, revealed strong positive staining for morbillivirus antigen associated with cerebral cortical pathology in wild cetacean number 20 and with cerebral and pulmonary pathology in wild cetacean number 24. No pulmonary IHC staining was detected in wild cetacean number 27. The RT-PCR performed on samples from three wild cetaceans did not detect morbilliviral RNA from wild cetacean number 5. Morbilliviral RNA was detected from wild cetaceans 20 and 24, with subsequent sequence analysis confirming CMV infection in both.
Captive cetaceans
Two of 13 (15%; 95% CI 1.9-45.5%) captive cetaceans sampled between November 2005 and January 2011 had CMVneutralizing antibodies. Both were offshore bottlenose dolphins that were wild caught in 1985 (Table 2) .
DISCUSSION
In a previous study assessing morbilliviral antibody data from cetaceans within Australian waters, eight animals were tested: one killer whale (Orcinus orca), one spectacled porpoise (Phocoena dioptrica), and six offshore bottlenose dolphins, with only one offshore bottlenose dolphin detected with CMV-specific antibodies (Van Bressem et al., 2001) . In our study, we detected antibodies against CMV in an additional four cetacean species. The sample population for each cetacean species in our study included only live stranded, injured, and trapped animals. The observed antibody prevalences may differ from those in wild populations. If marine mammals with morbilliviral disease are more likely than unaffected animals to be stranded in a moribund state (Reidarson et al., 1998) , our sampling method has potential for selection bias, and prevalences pooled across clinically diseased and healthy animals would be upwardly biased relative to prevalences in the wild populations. This is unavoidable with such a study and it is consistent with previously reported cetacean morbilliviral seroepidemiologic surveys (Duignan et al., 1995b; Reidarson et al., 1998; Van Bressem et al., 1998) . Such bias seems unlikely among clinically healthy animals, assuming previous morbillivirus infection does not affect risk of being stranded, trapped, or injured. We utilized the morbillivirus SNT, which has been used extensively for the assessment of individual animal CMV antibody status as well as for epidemiologic studies. It is considered to be highly sensitive and specific for the detection of morbillivirus antibody in marine mammals (Saliki and Lehenbauer, 2001; Van Bressem et al., 2001; Saliki et al., 2002) . Endemic CMV infection has been identified in populations of pilot whales and Fraser's dolphins (Duignan et al., 1995b; Van Bressem et al., 2001 ). We report a high CMV antibody prevalence (83%, 5/6) in melon-headed whales and CMV-specific antibodies in both sexually mature (adults) and immature (juveniles and subadults) males and females, in the absence of apparent disease outbreaks in this species over the study period (Greenland and Limpus, 2008) . As melon-headed whales are highly social, congregate in large pods, and often associate with other cetaceans (Jefferson et al., 1993) , there is potential for this species to serve as a reservoir of CMV infection for other cetacean species. However, larger studies would be needed to elucidate the role of melon-headed whales in the epidemiology of CMV infection along the east coast of Australia. Our finding of CMV antibody in 4/14 inshore bottlenose dolphins demonstrates that CMV infection occurs in this species. However, they typically live in small groups (Jefferson et al., 1993) and therefore would not be suitable candidates to serve as reservoirs for CMV.
Pathology and CMV RNA in affected tissues were only demonstrated in two study animals; both were immature offshore bottlenose dolphins, one of which (number 24) was the first reported case of a cetacean mortality due to morbillivirus infection in the southern hemisphere (Stone et al., 2011) . Histopathology associated with cetacean morbillivirus infection commonly includes nonsuppurative bronchointerstitial pneumonia or nonsuppurative encephalitis (Kennedy, 1998; Di Guardo et al., 2005) . Excluding the CMV infections confirmed in wild cetaceans 20 and 24, a further 11 animals (2, 3, 5, 6, 7, 11, 12, 14, 15, 21, and 27 ) had histopathologic evidence of pneumonia or central nervous system (CNS) inflammation with six of these animals (2, 3, 5, 7, 12, and 21) having CMV antibody. Characteristic findings of CMV-induced pathology, including viral inclusions or multinucleated syncytia (Di Guardo et al., 2005) , were absent in all cases except for wild cetacean 5, for which intranuclear inclusions were identified in the brain. Although definitive confirmation of CMV-induced disease was not established in these 11 animals, as RT-PCR was performed on formalin-fixed tissues (wild cetacean 5), the possibility of a falsenegative RT-PCR result could not be discounted. Nor can we dismiss the possibility that the described pulmonary or CNS histopathologic changes identified within any of the remaining nine animals, that did not have further CMV-specific diagnostic investigative procedures performed, may have been caused by CMV infection. It was not possible to perform retrospective morbillivirus-specific analysis (e.g., IHC) to investigate further a potential causative role of CMV infection in all animals with pulmonary or CNS inflammation. However, the antibody prevalence in animals with histopathologic evidence of pulmonary or CNS inflammation was not significantly different from that of animals without such pathology. One explanation for this is that study animals were exposed to etiologies not identified via routine histopathology, bacteriology, or mycology techniques, and for which further specific investigations were not performed. Even though, over the study period, there were no reports of unusual increases in cetacean mortalities or mass strandings in the study area (Greenland and Limpus, 2008) , the antibody prevalence was much higher in clinically diseased animals than nondiseased animals. Along with the pathology and CMV RNA in affected tissues in wild cetaceans 20 and 24, these findings confirm that CMV can cause disease in cetaceans within Australian waters.
Two of 13 (15%) captive cetaceans sampled between November 2005 and January 2011 had CMV-neutralizing antibodies. Both were offshore bottlenose dolphins that were wild caught in 1985. These dolphins may have been infected either in the wild or in captivity but it seems highly likely that both animals had been infected with CMV prior to capture. Morbilliviral infection induces long-lasting humoral immunity and morbilliviruses are highly transmissible (Black, 1991) ; therefore, given that both animals had frequent and recurrent direct contact with all of the other 11 antibody-negative captive animals, it would be expected that at least some of the other animals would have seroconverted if infection had occurred while in captivity. Van Bressem et al. (2001) reported similar observations in cetaceans. Given that it is highly unlikely that CMV infection of the two wild-caught captive antibody-positive dolphins in the current study occurred in captivity, CMV infection appears to have been present within Australian wild cetaceans since at least 1985. Furthermore, given that the captive cetaceans were mostly naïve (CMV antibody-negative), this population would be prone to a significant mortality event as a result of CMV introduction. Strict quarantine procedures should therefore be enforced when injured or stranded cetaceans are hospitalized and rehabilitated at Australian zoos and marine parks, and the protection of captive cetacean populations with live attenuated vaccines may also warrant further investigation .
In summary, we demonstrated that morbillivirus infection has occurred in multiple cetacean species without widespread cetacean mortality along the coast of southeastern Queensland and northern New South Wales. Clinical disease and death of two immature Australian offshore bottlenose dolphins was directly attributed to CMV infection. Clinically diseased animals were significantly more likely to have CMV-neutralizing antibodies than nondiseased animals, providing further supportive evidence that CMV causes disease in cetaceans within this region. Morbillivirus infection should be included in the differential diagnosis of diseased cetaceans in Australia, and we recommend submission of fresh and fixed tissue specimens (particularly lung and brain) from deceased cetaceans to investigate further the causative role of morbillivirus infection via specific techniques as IHC, electron microscopy, and RT-PCR, particularly if there are histopathologic changes typical of CMV infection (Kennedy 1998; Di Guardo et al., 2005) . Larger studies are required to clarify further the epidemiology, geographical distribution, and prevalence of CMV infection in cetaceans within Australian waters, and retrospective CMV-specific IHC analysis of relevant archived histopathology case material could also be informative.
